Aclarion, Inc. (ACON) Stock Price & Analysis
Aclarion, Inc. (ACON) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $1.22 (-13.92%), as of the Nov 20, 2026 trading session; market cap $3.52M.
Educational signal · not a buy or sell recommendation · How to read this
Aclarion, Inc. · ACON · NASDAQ
Aclarion, Inc. develops software applications for magnetic resonance spectroscopy (MRS) in the United States. Its NOCISCAN-LS Post-Processor suite calculates degenerative pain biomarkers and provides clinical decision support.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Aclarion (ACON)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality and weak growth, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Sound; Valuation: Fair; Growth Durability: Fading; Momentum: Slipping.
- EPS beat 0 of the last 4 reports
- Altman Z -4.64 · Piotroski F 2
- ROE -74.1% · ROA -45.8% · current ratio 14.17
Holding back: weak fundamentals, soft growth, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.22 | |
| Change on the day | -13.92% | |
| Market capitalisation | $3.52M | — |
| Shares traded on the day | 44.9K |
Price & events
Other perspectives
Council score for Aclarion (ACON): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Aclarion (ACON), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Aclarion, Inc. (ACON) is listed on NASDAQ. It employs 10 people. The market values it at $3.52M.
What do the latest results show for Aclarion (ACON)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $18,942 | -$2M | -$2.93 (diluted) |
| Q4 FY2025 | $18,479 | -$2M | — |
| Q1 FY2026 | $21,140 | -$3M | -$1.34 (diluted) |
| Q2 FY2026 | $25,208 | -$3M | -$1.12 (diluted) |
What are the financial strengths and risks for Aclarion (ACON)?
Short answer · as of
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z -4.64 · Piotroski F 2. Trailing ratios: ROE -74.1% · ROA -45.8% · current ratio 14.17.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -4.64 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-74.1%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
How is Aclarion scored?
Short answer · as of
A same-model peer rank is unavailable in the current peer set. The MoonshotScore combines business quality, financial safety, valuation, growth durability and momentum; open “Why this rating?” for the method and drivers.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 17, 2026
- Transactions
- 15
- Identified insiders
- 10
- Purchases
- 6
- Sales
- 0
- Other transactions
- 9
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ACON in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ACON in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Aclarion (ACON)?
Aclarion Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ACON research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ACON?
ACON carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Aclarion, Inc. develops software applications for magnetic resonance spectroscopy (MRS) in the United States.
Is ACON a good stock to buy?
Stock Expert AI does not rate ACON buy, sell or hold. Aclarion, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ACON stock price today?
The last price recorded for Aclarion, Inc. (ACON), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Aclarion, Inc. do?
Aclarion, Inc. is a healthcare technology company specializing in software applications for magnetic resonance spectroscopy (MRS) within the United States. Its primary offering is the NOCISCAN-LS Post-Processor suite, which includes two key components.
What are the key factors to evaluate for ACON?
Aclarion, Inc. (ACON) holds a MoonshotScore in the low range. Increased adoption of MRS technology for pain assessment: As healthcare systems globally, and particularly in the United States, increasingly prioritize objective and data-driven diagnostics for chronic pain conditions, the utility of Magnetic Resonance Spectroscopy (MRS) in identifying degenerative pain biomarkers is expected to grow. Not financial advice.
How frequently does ACON data refresh on this page?
ACON's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ACON's recent stock price performance?
Aclarion, Inc. (ACON) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized software for magnetic resonance spectroscopy (MRS) targeting degenerative pain biomarkers. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACON overvalued or undervalued right now?
Aclarion, Inc. (ACON) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ACON?
Fractional-share availability for Aclarion, Inc. (ACON) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 11 figures on this page — 8 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com